Dr. Alba studied English Literature and Biology as an undergraduate at Washington University in St. Louis, earned his MD at the Mount Sinai School of Medicine, and then completed both Internal Medicine and Pulmonary and Critical Care Medicine training at Massachusetts General Hospital (MGH). As an Assistant Professor of Medicine at Harvard Medical School and Pulmonary and Critical Care Physician at MGH, Dr. Alba is actively engaged in clinical care, research, and teaching. Dr. Alba's clinical interests include general pulmonary and critical care, pulmonary vascular diseases, dyspnea and exercise intolerance, and long-term pulmonary vascular recovery following critical illness, especially acute respiratory distress syndrome (ARDS).
Dr. Alba's research focuses on mechanisms of pulmonary vascular thrombosis and chronic thromboembolism and acute pulmonary vascular dysfunction and recovery in ARDS. Dr. Alba co-directs the MGH Program for Advancing Critical Care Translational Science (PACCTS), a comprehensive biorepository for critical illness syndromes, and he is Associate Director of the Coronavirus Recovery (CORE) clinic where he helps to care for and study the pulmonary complications of COVID-19 and ARDS. As an educator, Dr. Alba enjoys teaching and training medical students, residents, and fellows in the Medical Intensive Care Unit, teaches pulmonary physiology at Harvard Medical School, and is the recipient of accomplished teaching citations and a patient safety star related to efforts in quality improvement.
Treats:
Languages:
Mass General Pulmonary & Critical Care
55 Fruit St.
Boston, MA 02114
Phone: 617-726-1721
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Alba conducts basic and translational research in pulmonary vascular disease with the goal of identifying novel therapeutic targets and treatment modalities. The current work is focused on how local hypoxia results in endothelial dysfunction to affect platelet-endothelial cell interactions in the pulmonary circulation in a host of pulmonary disorders, ranging from chronic thromboembolic pulmonary hypertension to acute respiratory distress syndrome (ARDS), including COVID-19. His research has been supported by a National Research Service Award from the NIH NHLBI, a Harvard Catalyst KL2, the MGH Center for Diversity and Inclusion Physician Scientist Development Award, the MGH Department of Medicine Sanchez and Ferguson Research Faculty Award, the NIH Loan Repayment Program, and the Harold Amos Medical Faculty Development Program award jointly funded by the American Thoracic Society (ATS), CHEST Foundation, and the American Lung Association (ALA), a career development award intended to increase the diversity of academic medicine. He is a member of the ATS Pulmonary Circulation Programming Committee and the American Heart Association (AHA) 3CPR Scientific and Clinical Education Lifelong Learning Committee. He is a sub-investigator for the Boston COVID-19 Recovery Cohort, part of the multi-center NIH RECOVER study, and is collaborating on several projects to evaluate post-infectious endothelial dysfunction and small airways disease. For his research accomplishments, Dr. Alba was honored with an American Society of Clinical Investigation (ASCI) Young Physician-Scientist Award in 2023.
Selected publications:
Alba GA, Samokhin AO, Wang RS, Zhang YY, Wertheim BM, Arons E, Greenfield EA, Lundberg Slingsby MH, Ceglowski JR, Haley KJ, Bowman FP, Yu YR, Haney JC, Eng G, Mitchell RN,Sheets A, Vargas SO, Seo S, Channick RN, Leary PJ, Rajagopal S, Loscalzo J, Battinelli EM, Maron BA. NEDD9 is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation. Am J Respir Crit Care Med. 2021 Jun 15;203(12):1533-1545. doi:10.1164/rccm.202003-0719OC. PMCID: PMC8483217.
Alba GA, Ziehr DR, Rouvina JN, Hariri LP, Knipe RS, Medoff BD, Hibbert KA, Kowal A, Hoenstine C, Ginns LC, Lewis GD, Hardin CC. Exercise performance in patients with post-acute sequelae of SARS- CoV-2 infection compared to patients with unexplained dyspnea. EClinicalMedicine. 2021 Aug 28;39:101066. doi: 10.1016/j.eclinm.2021.101066. PMCID: PMC8401400.
Alba GA, Samokhin AO, Wang RS, Wertheim BM, Haley KJ, Padera RF, Vargas SO, Rosas IO, Hariri LP, Shih A, Thompson BT, Mitchell RN, Maron BA. Pulmonary Endothelial NEDD9 and the Prothrombotic Pathophenotype of Acute Respiratory Distress Syndrome due to SARS-CoV-2 Infection. Pulm Circ. 2022 May 11;12(2):e12071. doi: 10.1002/pul2.12071. PMCID: PMC9111030.
Alladina JW, Giacona FL, Haring AM, Hibbert KA, Medoff BD, Schmidt EP, Thompson BT, Maron BA, Alba GA. Circulating Biomarkers of Endothelial Dysfunction Associated With Ventilatory Ratio and Mortality in ARDS Resulting From SARS-CoV-2 Infection Treated With Anti-Inflammatory Therapies. CHEST Critical Care 2024; 2(2):100054. doi: 10.1016/j.chstcc.2024.100054.
Alba GA, Zhou IY, Mascia M, Magaletta M, Alladina JW, Giacona FL, Ginns LC, Caravan P, Maron BA, Montesi SB. Plasma NEDD9 is increased following SARS-CoV-2 infection and associates with indices of pulmonary vascular dysfunction. Pulm Circ. 2024 Mar 18;14(1):e12356. doi: 10.1002/pul2.12356. PMCID: 10946282.
Click Here
